Sign In
Last checked at 
2 Apr 2024 07:00
Director / PDMR / PCA Shareholding & TR-1 Notification
Belfast and London, 2 April 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, announces that on 28 March 2024, Peter Keeling, co-founder and Executive Director of Diaceutics, and Delia Keeling (Peter Keeling's spouse and a PCA), cumulatively sold 1,500,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of 102 pence per Ordinary Share. As a result of the sale, Peter and Delia Keeling's combined shareholding in Diaceutics is 15,752,049 Ordinary Shares representing approximately 18.60% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person responsible for making this announcement on behalf of the Company is Nick Roberts, Chief Financial Officer.
Enquiries:
Diaceutics PLC | |
Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer
| Tel: +44 (0)28 9040 6500 investorrelations@diaceutics.com |
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison | |
Nick Harland | |
Kate Hanshaw | |
Alma Strategic Communications | Tel: +44(0)20 3405 0205 |
Caroline Forde, Kinvara Verdon, Kieran Breheny | diaceutics@almastrategic.com |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Peter Keeling | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Executive Director | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Sale | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) | Volume(s) | ||||||
£1.02 | 750,000 | ||||||
d. | Date of the transaction | 28 March 2024 | |||||
e. | Place of the transaction | AIM Market of the London Stock Exchange | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Delia Keeling | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | PCA | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Sale | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) | Volume(s) | ||||||
£1.02 | 750,000 | ||||||
d. | Date of the transaction | 28 March 2024 | |||||
e. | Place of the transaction | AIM Market of the London Stock Exchange | |||||
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS | ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: | Diaceutics PLC ORD GBP0.002 | |||||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
Non-UK issuer | ||||||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments | ||||||
An event changing the breakdown of voting rights | ||||||
Other (please specify) iii: | ||||||
3. Details of person subject to the notification obligation iv | ||||||
Name | Peter & Delia Keeling | |||||
City and country of registered office (if applicable) | NA | |||||
4. Full name of shareholder(s) (if different from 3.) v | ||||||
Name | ||||||
City and country of registered office (if applicable) | ||||||
5. Date on which the threshold was crossed or reached vi: | 28 March, 2024 | |||||
6. Date on which issuer notified: | 28 March, 2024 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
% of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments(total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer (8.A + 8.B) vii | |||
Resulting situation on the date on which threshold was crossed or reached | 18.60% | 18.60% | ||||
Position of previous notification (if applicable) | 20.37% | 20.37% | ||||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type ofshares ISIN code (if possible) | Number of voting rights ix | % of voting rights | |||||||
Direct (DTR5.1) | Indirect (DTR5.2.1) | Direct (DTR5.1) | Indirect (DTR5.2.1) | ||||||
GB00BJQTGV64
| 15,752,049 | 18.60% | |||||||
SUBTOTAL 8. A | 15,752,049 | ||||||||
| |||||||||
B 1: Financial Instruments according to DTR5.3.1R (1) (a) | |||||||||
Type of financial instrument | Expirationdate x | Exercise/Conversion Period xi | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
SUBTOTAL 8. B 1 | |||||||||
| |||||||||
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) | |||||||||
Type of financial instrument | Expirationdate x | Exercise/Conversion Period xi | Physical or cash Settlement xii | Number of voting rights | % of voting rights | ||||
| SUBTOTAL 8.B.2 | ||||||||
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii | ||||
Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv | ||||
Name xv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
| ||||
10. In case of proxy voting, please identify: | ||||
Name of the proxy holder | ||||
The number and % of voting rights held | ||||
The date until which the voting rights will be held | ||||
11. Additional information xvi | ||||
Place of completion | AIM Stock Exchange, London |
Date of completion | 28, March 2024 |
Follow the stocks
